As copay accumulator programs continue to increase, stakeholders look to understand the trends and potential steps forward. Join our Lash Group and Xcenda experts to learn more about the evolution and advancement in payer tactics to manage specialty drugs, gauge the impact of increasing out-of-pocket expenses on patients, the increase in copay accumulator and maximum allowable models, and the impact on patients and manufacturers.